The usage of immunosuppressant agents and secondary infections in patients with COVID-19 in the intensive care unit: a retrospective study.
Humans
Male
Female
Intensive Care Units
Retrospective Studies
COVID-19
/ mortality
Middle Aged
Immunosuppressive Agents
/ therapeutic use
Aged
Dexamethasone
/ therapeutic use
COVID-19 Drug Treatment
Methylprednisolone
/ therapeutic use
SARS-CoV-2
/ isolation & purification
Antibodies, Monoclonal, Humanized
/ therapeutic use
Adult
COVID-19 infection
Dexamethasone
Immunosuppressant
Intensive care unit
Interleukin
Methylprednisolone
Pandemic
Propensity score matching
Retrospectively
Secondary
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 09 2024
09 09 2024
Historique:
received:
24
05
2024
accepted:
02
09
2024
medline:
10
9
2024
pubmed:
10
9
2024
entrez:
9
9
2024
Statut:
epublish
Résumé
Although COVID-19 infection is an immunosuppressant disease, many immunosuppressant agents, such as pulse methylprednisolone (PMP), dexamethasone (DXM), and tocilizumab (TCZ), were used during the pandemic. Secondary infections in patients with COVID-19 have been reported recently. This study investigated these agents' effects on secondary infections and outcomes in patients with COVID-19 in intensive care units (ICUs). This study was designed retrospectively, and all data were collected from the tertiary intensive care units of six hospitals between March 2020 and October 2021. All patients were divided into three groups: Group I [GI, PMP (-), DXM (-) and TCZ (-)], Group II [GII, PMP (+), DXM (+)], and Group III [GIII, PMP (+), DXM (+), TCZ (+)]. Demographic data, P
Identifiants
pubmed: 39251824
doi: 10.1038/s41598-024-71912-3
pii: 10.1038/s41598-024-71912-3
doi:
Substances chimiques
Immunosuppressive Agents
0
Dexamethasone
7S5I7G3JQL
Methylprednisolone
X4W7ZR7023
tocilizumab
I031V2H011
Antibodies, Monoclonal, Humanized
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20991Informations de copyright
© 2024. The Author(s).
Références
Dessie, Z. G. & Zewotir, T. Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect. Dis. 21, 855 (2021).
pubmed: 34418980
pmcid: 8380115
doi: 10.1186/s12879-021-06536-3
Biran, N. et al. Tocilizumab among patients with COVID-19 in the intensive care unit: A multicentre observational study. Lancet Rheumatol. 2, e603–e612 (2020).
pubmed: 32838323
pmcid: 7428303
doi: 10.1016/S2665-9913(20)30277-0
Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. U. S. A. 117, 10970–10975 (2020).
pubmed: 32350134
pmcid: 7245089
doi: 10.1073/pnas.2005615117
Guaraldi, G. et al. Tocilizumab in patients with severe COVID-19: A retrospective cohort study. Lancet Rheumatol. 2, e474–e484 (2020).
pubmed: 32835257
pmcid: 7314456
doi: 10.1016/S2665-9913(20)30173-9
RECOVERY Collaborative Group et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693–704 (2021).
doi: 10.1056/NEJMoa2021436
Edalatifard, M. et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: Results from a randomised controlled clinical trial. Eur. Respir. J. 56, 2002808 (2020).
pubmed: 32943404
pmcid: 7758541
doi: 10.1183/13993003.02808-2020
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA 324, 1330–1341 (2020).
doi: 10.1001/jama.2020.17023
Bardi, T. et al. Nosocomial infections associated to COVID-19 in the intensive care unit: Clinical characteristics and outcome. Eur. J. Clin. Microbiol. Infect. Dis. 40, 495–502 (2021).
pubmed: 33389263
pmcid: 7778834
doi: 10.1007/s10096-020-04142-w
Lansbury, L., Lim, B., Baskaran, V. & Lim, W. S. Co-infections in people with COVID-19: A systematic review and meta-analysis. J. Infect. 81, 266–275 (2020).
pubmed: 32473235
pmcid: 7255350
doi: 10.1016/j.jinf.2020.05.046
Pedersen, S. F. & Ho, Y.-C. SARS-CoV-2: A storm is raging. J. Clin. Invest. 130, 2202–2205 (2020).
pubmed: 32217834
pmcid: 7190904
doi: 10.1172/JCI137647
Picchianti Diamanti, A., Rosado, M. M., Pioli, C., Sesti, G. & Laganà, B. Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: The fragile balance between infections and autoimmunity. Int. J. Mol. Sci. 21, 3330 (2020).
pubmed: 32397174
pmcid: 7247555
doi: 10.3390/ijms21093330
Baskaran, V. et al. Co-infection in critically ill patients with COVID-19: an observational cohort study from England. J. Med. Microbiol. 70, 001350 (2021).
pubmed: 33861190
pmcid: 8289210
doi: 10.1099/jmm.0.001350
Biasio, D., Mittel, J. C. & Mueller, A. M. Frailty in critical care medicine: A review. Anesth. Analg. 130, 1462–1473 (2020).
pubmed: 32384336
pmcid: 7426653
doi: 10.1213/ANE.0000000000004665
Russell, C. D. et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: A multicentre, prospective cohort study. The Lancet Microbe 2, e354–e365 (2021).
pubmed: 34100002
pmcid: 8172149
doi: 10.1016/S2666-5247(21)00090-2
https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf .
Miller, J. M. et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the infectious diseases society of America and the American society for microbiologya. Clin. Infect. Dis. 67, 813–816 (2018).
pubmed: 30169655
doi: 10.1093/cid/ciy584
Doern, G. V. et al. Practical guidance for clinical microbiology laboratories: A comprehensive update on the problem of blood culture contamination and a discussion of methods for addressing the problem. Clin. Microbiol. Rev. 33, 10–1128 (2019).
doi: 10.1128/CMR.00009-19
Bassetti, M. et al. EORTC/MSGERC definitions of invasive fungal diseases: Summary of activities of the intensive care unit working group. Clin. Infect. Dis. 72, S121–S127 (2021).
pubmed: 33709127
doi: 10.1093/cid/ciaa1751
Kotton, C. N. et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102, 900–931. https://doi.org/10.1097/tp.0000000000002191 (2018).
doi: 10.1097/tp.0000000000002191
pubmed: 29596116
Traylen, C. M. et al. Virus reactivation: A panoramic view in human infections. Future Virol. 6, 451–463 (2011).
pubmed: 21799704
pmcid: 3142679
doi: 10.2217/fvl.11.21
CAUTI guidelines. https://www.cdc.gov/infectioncontrol/guidelines/cauti/index.html (2019).
Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China. Intensive Care Med. 46, 846–848 (2020).
pubmed: 32125452
doi: 10.1007/s00134-020-05991-x
Mehta, P. et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034 (2020).
pubmed: 32192578
pmcid: 7270045
doi: 10.1016/S0140-6736(20)30628-0
Henderson, L. A. et al. On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis Rheumatol. 72, 1059–1063 (2020).
pubmed: 32293098
pmcid: 7262347
doi: 10.1002/art.41285
Gorham, J. et al. Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis. PLoS One 15, e0244628 (2020).
pubmed: 33382773
pmcid: 7774924
doi: 10.1371/journal.pone.0244628
Seymour, C. W. et al. Assessment of clinical criteria for sepsis: For the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315, 762–774 (2016).
pubmed: 26903335
pmcid: 5433435
doi: 10.1001/jama.2016.0288
Alhazzani, W. et al. Surviving sepsis campaign: Guidelines on the management of critically Ill adults with coronavirus disease 2019 (COVID-19). Crit. Care Med. 48, e440–e469 (2020).
pubmed: 32224769
doi: 10.1097/CCM.0000000000004363
François, B., Laterre, P.-F., Luyt, C.-E. & Chastre, J. The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients. Crit. Care 24, 289 (2020).
pubmed: 32503590
pmcid: 7273812
doi: 10.1186/s13054-020-03013-2
Grom, A. A., Horne, A. & De Benedetti, F. Macrophage activation syndrome in the era of biologic therapy. Nat. Rev. Rheumatol. 12, 259–268 (2016).
pubmed: 27009539
pmcid: 5851441
doi: 10.1038/nrrheum.2015.179
Van den Eynde, E. et al. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital. Infect. Dis. (Lond.) 53, 291–302 (2021).
pubmed: 33620019
doi: 10.1080/23744235.2021.1884286
Diao, B. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 11, 827 (2020).
pubmed: 32425950
pmcid: 7205903
doi: 10.3389/fimmu.2020.00827
Gordon, A. C., Angus, D. C. & Derde, L. P. G. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N. Engl. J. Med. 385, 1147–1149 (2021).
pubmed: 34407335
doi: 10.1056/NEJMc2108482
Morris, C., Kohler, A. & Corte, D. Co-infection and ICU-acquired infection in COIVD-19 ICU patients: A secondary analysis of the UNITE-COVID data set. Crit. Care 26, 236 (2022).
doi: 10.1186/s13054-022-04108-8
Li, H. et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: A systematic review and meta-analysis. Leukemia 34, 1503–1511 (2020).
pubmed: 32372026
pmcid: 7199650
doi: 10.1038/s41375-020-0848-3
Meduri, G. U., Siemieniuk, R. A. C., Ness, R. A. & Seyler, S. J. Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J. Intensive Care Med. 6, 53 (2018).
doi: 10.1186/s40560-018-0321-9
Bayo, M., Palacián Ruíz, S., Moreno Hijazo, M. P. & Villuendas Usón, M. Bacteremia during COVID-19 pandemic in a tertiary hospital in Spain. Enferm. Infecc. Microbiol. Clin. 40, 183–186 (2021).
doi: 10.1016/j.eimc.2021.01.015
Meynaar, I. A., van Rijn, S., Ottens, T. H., van Burgel, N. D. & van Nieuwkoop, C. Increased risk of central line-associated bloodstream infection in COVID-19 patients associated with dexamethasone but not with interleukin antagonists. Intensive Care Med. 48, 954–957 (2022).
pubmed: 35670819
pmcid: 9171741
doi: 10.1007/s00134-022-06750-w
Somers, E. C. et al. Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. Clin. Infect. Dis. 73, e445–e454 (2021).
pubmed: 32651997
doi: 10.1093/cid/ciaa954
Kaçmaz, B. et al. COVID-19 associated bacterial infections in intensive care unit: A case control study. Sci. Rep. 13, 13345 (2023).
pubmed: 37587143
pmcid: 10432560
doi: 10.1038/s41598-023-39632-2
Sebba, A. Tocilizumab: The first interleukin-6-receptor inhibitor. Am. J. Health. Syst. Pharm. 65, 1413–1418 (2008).
pubmed: 18653811
doi: 10.2146/ajhp070449
Hofmaenner, D. A. et al. What every intensivist should know about Tocilizumab. Crit. Care 25, 262 (2021).
pubmed: 34315504
pmcid: 8313874
doi: 10.1186/s13054-021-03696-1
Edwards, C. J. IL-6 inhibition and infection: treating patients with tocilizumab. Rheumatology 51, 769–770 (2012).
pubmed: 21900369
doi: 10.1093/rheumatology/ker311
Schäcke, H., Döcke, W. D. & Asadullah, K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96, 23–43 (2002).
pubmed: 12441176
doi: 10.1016/S0163-7258(02)00297-8
Cain, D. W. & Cidlowski, J. A. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 17, 233–247 (2017).
pubmed: 28192415
pmcid: 9761406
doi: 10.1038/nri.2017.1
https://covid19.saglik.gov.tr/TR-66299/covid-19-tedavi.html .
Guidelines archive. COVID-19 Treatment Guidelines https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/guidelines-archive/ .
Rasulo, F. A., Piva, S. & Latronico, N. Long-term complications of COVID-19 in ICU survivors: What do we know?. Minerva anestesiol. 88, 72–79 (2022).
pubmed: 34709019
doi: 10.23736/S0375-9393.21.16032-8